Tempus AI (NasdaqGS:TEM) has launched a new AI-driven HRD-RNA algorithm aimed at improving cancer diagnostics. The company has entered a partnership with Median Technologies to bring advanced lung ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Tempus AI’s fair value estimate has been trimmed slightly from US$87.92 to US$86.71 per share, a small adjustment that still matters if you are tracking valuation closely. That shift sits alongside ...